Page 261 - ASHG 2013 Program Guide

248  
POSTER SESSIONS
W=W
ednesday authors will present; T=Thursday authors will present; F=Friday authors will pr
esent
3302
F Expression-based classification of melanoma
cell sensitivity to temozolomide.
T. Zhang, M. Xu, C.
Sereduk, D. Chow, J. Trent, H. Yin, K. Brown.
3303
W Mining of TCGA data links AGR3 dysregulation
to surfactant homeostasis in lung cancer.
A. Umesh,
J. Delaney, J. Shima, J. Park, R. Wisotzkey, M. Shekar, I.
Kupershmidt.
3304
T Downregulation of
SIDT1
gene in leukemia.
J.
Mazzeu, S. G. Magalhães, L. H. Sakamoto, R. Camargo,
M. B. Daldegan, B. D. Lima.
3305
F Genetic polymorphisms in the 9p21 region
associated with multiple cancers.
W. Li, R. Pfeiffer, F. Gu,
Z. Wang, M. Yeager, X. Deng, L. Amundadottir, J. Luo, S.
Chanock, N. Chatterjee, M. Tucker, A. Goldstein, X. Yang.
3306
W Cryptic mutations in introns and exons leading
to splice alterations in breast cancer genes.
S. Casadei,
T. Walsh, C. H. Spurrel, A. M. Thornton, J. B. Mandell, S.
M. Stray, M. K. Lee, M. C. King.
3307
T
MEIS1
silencing influences the exp ession of
cancer/testis antigen
SSX2
in myeloid leukemia cell
line K562.
J. Torres-Flores, A. Aguilar-Lemarroy, A. Bravo-
Cuellar, L. F. Jave-Suarez.
3308
F Monoallelic epigenetic silencing of the Apc
tumor suppressor gene and parent of origin effects in
a rat model of colon cancer.
J. Amos-Landgraf, A. Irving,
M. Ford, W. Dove.
3309
W Evaluation of a cancer gene sequencing panel
in a hereditary risk assessment clinic.
Y. Kobayashi,
A. W. Kurian, E. Hare, M. A. Mills, K. E. Kingham, A. S.
Whittemore, V. McGuire, G. Gong, U. Ladabaum, M.
Cargill, J. M. Ford.
3310
T Novel integrative genomics approach to
biomarker discovery in prostate cancer.
C. Hicks, L.
Miele, T. Koganti, J. Sitthi-Amorn, S. Vijayakumar.
3311
F Exomic sequencing to identify germline variants
in familial melanoma.
H. N. Shabbir, M. T. Landi.
3312
W Molecular classification of myelop oliferative
neoplasms patients in the State of Qatar according to
World Health Organization 2008 criteria.
N. Al-Dewik, Q.
Fernandes, Y. K. Naidu, N. Bonnin, E. Verger, B. Cassinat,
J. J. Kiladjian, H. El Ayoubi, M. Yassin.
3313
T Novel association between tanning addiction
and
PTCHD2
alleles using a whole exome variant array.
A. E. Bale, A. T. Dewan, L. M. Ferrucci, J. Gelernter, D. J.
Leffell, S. T. Mayne, J. Stapleton, B. Cartmel.
3314
F The PROFILE Feasibility Study: Genetic prostate
cancer risk stratification for targeted sc eening.
R. Eeles, E. Bancroft, N. Taylor, T. Dadaev, E. Page, D.
Keating, N. Borley, N. Desouza, C. Goh, E. Saunders, A.
Lee, D. Easton, A. Antoniou, Z. Kote-Jarai, E. Castro.
3291
W Estrogen and progesterone receptor gene
polymorphisms as risk factors for cervix cancer in
South Indian population.
P. Upendram, V. Kiran Kumar, S.
Poornima, A. Shah, Q. Hasan.
3292
T Fine-mapping of genome-wide association
study-identified risk loci for colorectal cancer.
H. Wang,
C. A. Haiman, T. Burnett, B. K. Fortini, L. K. Kolonel, B.
E. Henderson, L. B. Signorello, W. J. Blot, T. O. Keku, S.
I. Berndt, P. A. Newcomb, M. Pande, C. I. Amos, D. W.
West, G. Casey, R. S. Sandler, R. Haile, D. O. Stram, L. Le
Marchand.
3293
F Zinc transporter gene variants and susceptibility
to urological cancers.
L. Wu, K. Rabe, A. Parker, G.
Petersen.
3294
W The prevalence of the
HOXB13
G84E prostate
cancer risk allele in men treated with radical
prostatectomy.
K. A. Zuhlke, J. Beebe-Dimmer, C. Yee,
A. M. Johnson, P. C. Walsh, S. D. Isaacs, W. B. Isaacs, K.
A. Cooney.
3295
T Prevalence of germline mutation p.R337H in the
TP53
gene in families with multiple cases of cancer.
K.
C. Andrade, K. M. Santiago, A. Nobrega, F. P. Fortes, M.
I. Achatz.
3296
F Is
IGSF1
involved in human pituitary tumor
formation?
F. R. Faucz, A. D. Horvath, P. Xekouki, E.
Szarek, G. Evgenia, A. D. Manning, I. Levy, E. Saloustros,
R. B. de Alexandre, M. Nesterova, C. A. Stratakis.
3297
W Mutational landscape of candidate genes in
familial prostate cancer.
A. Johnson, K. Zuhlke, C. Plotts,
J. Douglas, S. Thibodeau, K. Cooney.
3298
T Development of a next-generation sequencing
panel to assess hereditary cancer risk that includes
clinical diagnostic analysis of the
BRCA1
and
BRCA2
genes.
B. Roa, K. Bowles, S. Bhatnagar, N. Gutin, A.
Murray, B. Wardell, M. Bastian, J. Mitchell, J. Chen, T.
Tran, D. Williams, J. Potter, S. Jammulapati, M. Perry, B.
Morris, K. Timms.
3299
F Development of 3C-based target sequencing
technology for candidate gene discovery in prostate
cancer.
M. J. Du, T. Z. Yuan, R. L. Dittmar, X. Y. Huang, S.
N. Thibodeau, L. Wang.
3300
W From GWAS to therapy: Fatty acid synthase in
uterine leiomyomata.
Z. Ordulu, M. Hayden, S. Eggert, B.
J. Quade, C. C. Morton.
3301
T Coding variants at the hexa-allelic amino acid 13
of
HLA-DRB1
explain independent SNP associations
with follicular lymphoma risk.
J. N. Foo, K. E. Smedby,
N. K. Akers, M. Berglund, I. D. Irwan, X. Jia, Y. Li, D. E. K.
Tan, J. X. Bei, J. Chang, L. Conde, H. Darabi, P. M. Bracci,
M. Melbye, H. O. Adami, B. Glimelius, D. Lin, W. H. Jia,
A. L. H. Seow, C. C. Khor, H. Hjalgrim, L. Padyukov, K.
Humphreys, G. Enblad, C. F. Skibola, P. I. W. de Bakker,
J. Liu.